Evidence map›Paper›PMID 34568803›Full record

ReviewJournal of translational autoimmunity2021

"Ways in which the neonatal Fc-receptor is involved in autoimmunity".

Juliette Lamamy, Pierre Boulard, Guillaume Brachet, Sébastien Tourlet, Valérie Gouilleux-Gruart, Yanis Ramdani

Open access · goldAbstract readReview
In one paragraph

Review in Journal of translational autoimmunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Novel Therapies to Address Unmet Needs in ITP.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Juliette LamamyEA7501, GICC, Université François Rabelais de Tours, F-37032, Tours, France.
Pierre BoulardLaboratoire d'immunologie, CHU Tours, F-37032, Tours, France.
Guillaume Brachetb2biopharma, Tours, France.
Sébastien TourletMyDisease2EZ, Fresnes, France.
Valérie Gouilleux-GruartEA7501, GICC, Université François Rabelais de Tours, F-37032, Tours, France.
Yanis RamdaniService de Médecine Interne, CHU Tours, F-37032, Tours, France.
Centre Hospitalier Universitaire de Tours · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the neonatal IgG Fc receptor (FcRn) was discovered, its role has evolved from immunoglobulin recycling and biodistribution to antigen presentation and immune complex routing, bringing it to the center of both humoral and cellular immune responses. FcRn is thus involved in the pathophysiology of immune-related diseases such as cancer, infection, and autoimmune disorders. This review focuses on the role of FcRn in autoimmunity, based on the available data from both animal models and human studies. The knowledge concerning ways in which FcRn is involved in autoimmune response has led to the development of inhibitors for the treatment of autoimmune diseases, also described here. Up to date, the literature remains scarce, shedding light on the need for further studies to fully understand the various pathophysiological roles of this unique receptor.

Indexed as

Autoimmune diseaseAutoimmunityFcRn, Neonatal Fc receptorIC, Immune complexesmAbs, Monoclonal antibodiesMonoclonal therapeutic antibodiesNeonatal Fc receptor

Identifiers

PMID34568803
PMCPMC8449123
OpenAlexW3200051523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.